Nanosphere Names Dr. Peter G. Schultz to Board of Directors
News Sep 29, 2005
Nanosphere, Inc. has announced Peter G. Schultz, Ph.D., has joined its board of directors.
Dr. Schultz's widely recognized scientific knowledge will enable him to provide strategic guidance to Nanosphere as it prepares to introduce the first system that enables ultra-sensitive detection of DNA, RNA and proteins on a single platform.
Dr. Schultz is internationally known as a pioneer in organic chemistry and biomedical research.
He is on the faculty at The Scripps Research Institute in La Jolla, Calif., where he holds the Scripps Family Chair as a professor of chemistry, and is director of the Genomics Institute of the Novartis Research Foundation, also in La Jolla.
He has developed many of the tools and techniques used in the field of combinatorial chemistry, which merges the tools and principles of chemistry with the molecules and processes of living cells to create molecules with new properties and functions.
He is a member of the National Academy of Sciences and the Institute of Medicine of the National Academy of Sciences.
“Dr. Schultz brings to Nanosphere's board a clear record of success in commercializing products based on molecular mechanisms of complex biological and chemical systems,” said William Moffitt, president and chief executive officer, Nanosphere.
“We believe his insight will be invaluable as we develop our nanoparticle-based systems and take them to a broad market.”
“Dr. Schultz offers a uniquely valuable perspective on moving technologies into production for global life sciences and medical organizations and will help Nanosphere deliver significant customer and shareholder value.”
Dr. Schultz said, “Nanosphere possesses a rare mix of truly cutting-edge technology, high-caliber management and clear market need for its product.”
“I'm pleased to join the company's board at an exciting time in Nanosphere's development, as it moves from early customer use of its core technology to broader deployment in the coming months.”
Dr. Schultz received bachelor's and doctoral degrees from the California Institute of Technology.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.